The global diet pills market is expected to reach a value of US$ 3.01 billion by 2030, according to some data from market research firms. This growth is driven by the rising prevalence of obesity and increased health awareness, as well as growing disposable incomes and concerns about maintaining a healthy lifestyle.
The diet pills market has been segmented into two types: over-the-counter and prescription. The prescription drugs segment currently holds the largest market share, as these pills are prescribed by medical professionals and are approved for long-term use. However, the over-the-counter segment is expected to grow steadily in the coming years due to the increased penetration of e-commerce and consumer knowledge.
The diet pills market has also been segmented by product type, with fat blocking and appetite suppression (both among over-the-counter products and prescription products) being the two main segments. The appetite suppression segment among otc diet pills currently holds a large share of the market due to its effectiveness and ingredients like caffeine and other stimulants.
However, the fat blockers segment is gaining popularity among young people and women seeking quick aesthetic results, and is preferred by self-directed consumers. There are also various fat burners specifically targeted towards women.
In terms of regional market share, North America currently dominates the diet pills market due to the high incidence of obesity and the presence of key players in the region. Europe is the second largest market, driven by regulatory approvals and the presence of key market players. Asia Pacific is expected to experience the highest growth rate in the coming years due to rising disposable incomes and government initiatives to curb obesity.
Some of the key players in the diet pills market include Novo Nordisk, Gelesis, Zoller Laboratories, GlaxoSmithKline, Chong’s Health Care, Herbalife, Currax Pharmaceuticals, Arena Pharmaceuticals, Nutrisystem, and F. Hoffmann-La Roche. These companies are focusing on product innovation and marketing strategies to gain a competitive edge in the market.
However, it has also been analyzed that the over-the-counter segment would be growing steadily in the forecast period because of the increased penetration of e-commerce and consumer knowledge.
The global diet pills market is segmented into:
- Fat Blocking
- Appetite Suppression
Excerpts from ‘By Region Segmentation’
The global diet pills market has been segmented into:
- North America
- Asia Pacific
- Rest of the World
According to experts who’ve observed numerous people who have struggled with obesity for most of their lives, the availability of new weight loss medications is always incredibly exciting for this audience. For years, people have tried various diets and exercise routines, but nothing has seemed to work for a lot of them in the long term. The idea of being able to take a medication that could help me lose weight and improve overall health is incredibly appealing.
According to a recent report by the US Government Accountability Office, less than 1 percent of the estimated 71 million US adults with obesity used weight loss medication from 2012 to 2016. However, doctors are saying that people are increasingly viewing obesity as a disease that needs to be treated, rather than a moral lapse or laziness. This shift in perception, combined with the availability of new medications, is leading to a dramatic demand for these drugs.
One such medication is semaglutide, which is currently in high demand. In fact, Dr. Fatima Stanford, an obesity medicine specialist at Massachusetts General in Boston, says that she can’t even get all of her patients on the drug due to supply constraints. She believes that there needs to be a focus on ramping up production in order to meet the demand.
Another medication that is currently generating a lot of interest is Wegovy. A four-week course of this drug has a list price of $1,349 per month, although patients with insurance that covers the drug pay less. Given that patients must stay on the drug for life in order to avoid putting the weight back on, obesity medications are expected to generate stable income for drugmakers over the long term.
Morgan Stanley forecasts Novo Nordisk and Lilly will capture about 40 per cent of the market, as they develop and launch up to a dozen obesity medicines currently in development between them. Several other biotech companies — Amgen, Altimmune, Zealand Pharma, Hanmi, Regor Therapeutics, Sciwind Biosciences and vTv Therapeutics — are at earlier stages of drug development.
The US Food and Drug Administration (FDA) had granted fast-track designation to Lilly’s weight loss drug Tirzepatide, which got its FDA approval.
Tirzepatide is a type of drug called a glucagon-like peptide 1 (GLP-1) agonist. These drugs were originally developed to help control blood sugar levels in people with diabetes, but they can also lead to substantial weight loss when administered as a once-weekly injection under the skin.
Tirzepatide is not the only drug in this class; Wegovy, another GLP-1 agonist, was recently approved for the treatment of obesity. But Tirzepatide has some key differences that could make it even more effective at helping people lose weight.
One of the biggest differences is the dosage. Tirzepatide is administered as a weekly injection, while Wegovy is taken daily. This means that Tirzepatide could be more convenient for patients, which could make it more appealing to people who are struggling with obesity.
Another key difference is the price. Lilly successfully launched a formulation of Tirzepatide, which it branded Mounjaro, earlier this year to treat type 2 diabetes. The list price for four weekly doses is $974, which is significantly less expensive than Wegovy.
SVB Securities, an investment bank, predicts that there will be high demand for Tirzepatide when it is approved for obesity. The bank forecasts that Tirzepatide will generate about $26bn in annual sales in 2030, with about one-third of this amount related to treating diabetes and two-thirds for obesity.
For years, the conventional wisdom on weight loss has been that it’s all about diet and exercise. Get-fit-quick schemes promise that if you’re willing to put in the effort and willpower, you can lose weight and get healthy. But what if that’s not the whole story?
Recent research suggests that genetics and environmental factors can make it extremely difficult, or even impossible, for some people to lose weight without outside help (like medications). And for those people, surgery has been the traditional solution. But there’s a less invasive option that has been sitting on the shelf for a while now: phentermine.
As one user states-
“As a patient who has struggled with my weight for many years, I was excited to hear about a study that suggests that phentermine may be a safe and effective way to achieve longer-lasting weight loss. However, I also understand that more research is needed to provide greater certainty about the drug’s effectiveness and safety.
I have been taking phentermine for several months now, and I have noticed a significant difference in my weight and overall health. I feel more energetic and motivated to eat healthy and exercise. However, I am also aware that the study did not examine the most effective dose of the drug, or potential side effects such as anxiety or insomnia.”
But consumers need to understand that the study only included people who did not have evidence of pre-existing heart disease, and most of the participants were young or middle-aged women. As a result, it is important for doctors to use caution when prescribing phentermine, and to carefully monitor their patients for any potential side effects. This is also one reason why otc phentermine alternatives or alternative brands from countries like Mexico became more popular recently.
Overall, those who lose weight with prescription products are grateful for the progress that they have made with the help of these diet solutions, but more research is needed to fully understand the potential risks and benefits of the drugs, especially with products like Mexican Phentermine. In the meantime, experts & market research firms will continue to work with doctors and pharmaceutical executives to ensure that people are using the medications safely and effectively.
Another popular product is Saxenda. According to one study by the manufacturer, many people who take Saxenda for weight loss lose at least 5% of their body weight. This may not seem like a lot, but for someone who is severely overweight, it can make a big difference in their health and quality of life.
One downside to GLP-1 drugs like Saxenda is their cost. While older generic medications can be very affordable, costing patients as little as $15 a month, newer brand-name GLP-1s can be much more expensive. For example, a month’s supply of weekly injections of Saxenda can cost around $1,400.
Despite the cost, we believe that GLP-1 drugs like Saxenda have been a valuable tool to a lot of people in their weight loss journeys. They have helped them achieve greater weight loss and improved their overall health.